Sovereign Pharma dispatches first batch of Remdesivir injections to Cipla

Manufacturing and packaging of the antiviral drug for Covid-19

Sovereign Pharma
Cipla’s First Batch of Remdesivir dispatched from Sovereign Pharma

The Daman-based Sovereign Pharma is manufacturing the antiviral drug for Indian pharmaceutical giant Cipla, as it continues to be one of the few effective ways to combat Covid-19. Established in 2003 as a contract manufacturing organization (CMO) to produce high-quality injectables for pharmaceutical companies worldwide, Sovereign now produces 350 million pieces each year. It sells over one billion injections by the number of doses every year.

As Indian medical authorities and the pharma industry are working relentlessly to provide medications to treat Coronavirus, Sovereign Pharma announced the dispatch of its first batch of Remdesivir injections for Cipla on 7 July 2020.

Sovereign Pharma dispatches the first batch of Remdesivir

In the absence of a definitive treatment line, the Indian government under the guidance of prime minister Narendra Modi has been instrumental in encouraging local drug manufacturers to identify potential treatments for the virus and ramp up production of the existing medications. Within the union territory of Daman and Diu, one of India’s pharmaceutical hubs, Sovereign Pharma has prepared the first batch of Remdesivir within record time. According to the press statement, the plant recently went through a meticulous inspection by the CDSCO and received necessary approvals from the authority within a week, under the guidance of administrator Praful Patel.

To commemorate the achievement, Anil Kumar Singh, advisor to the administrator, Dr A M Muthamma, secretary, Health and Family Welfare, Dr Rakesh Minhas, collector, Daman, Dr Vikramjit Singh, SP Daman, Dr Das, director Medical and Health Services and Drug Licensing Authority, and Dr Agarwal, drug inspector were present along with Kairus Dadachanji, managing director, and Rishad Dadachanji, director, Sovereign Pharma to flag off the first dispatch of Remdesivir from the Daman facility.

IMG 20200708 WA0008

“Our manufacturing sites remain compliant with the highest global standards and certifications at all times, as it is our constant endeavor to cater to the pharma industry’s ever-evolving requirements. Even in such unprecedented times, we are proud that our facility has been able to supply this medication in record time to one of our key clients,” shared Rishad Dadachanji.

Remdesivir is known for successfully reducing the virus load in Coronavirus patients, and has been going through tests for specific treatment for Covid-19. It has been authorized for emergency use or severe cases in several countries, including India.

“We have constantly been manufacturing Remdesivir since last month, and at our current capacity, we can supply 50,000 to 95,000 pieces of the injectable per month. We know how critical the situation is, especially with the pandemic still spreading across the country. Hence, we are in constant touch with all our clients, and ready to cater to their requirements with utmost priority,” Rishad said.

With the PM Modi government’s push to become a global pharmaceutical hub, India has been at the forefront for producing and distributing effective medications to fight Coronavirus. Cipla is amongst the six Indian generic pharma manufacturers that have signed non-exclusive voluntary licensing agreements with Gilead Sciences for its patented drug Veklury (Remdesivir). In turn, Cipla has signed a contract manufacturing agreement with BDR Pharmaceuticals, who have further transferred the formulation technology for manufacturing and packaging of the generic drug to Sovereign.

The Covid-19 pandemic led to the country-wide lockdown on 25 March 2020. It will be two years tomorrow as I write this. What have we learned in this time? Maybe the meaning of resilience since small companies like us have had to rely on our resources and the forbearance of our employees as we have struggled to produce our trade platforms.

The print and packaging industries have been fortunate, although the commercial printing industry is still to recover. We have learned more about the digital transformation that affects commercial printing and packaging. Ultimately digital will help print grow in a country where we are still far behind in our paper and print consumption and where digital is a leapfrog technology that will only increase the demand for print in the foreseeable future.

Web analytics show that we now have readership in North America and Europe amongst the 90 countries where our five platforms reach. Our traffic which more than doubled in 2020, has at times gone up by another 50% in 2021. And advertising which had fallen to pieces in 2020 and 2021, has started its return since January 2022.

As the economy approaches real growth with unevenness and shortages a given, we are looking forward to the PrintPack India exhibition in Greater Noida. We are again appointed to produce the Show Daily on all five days of the show from 26 to 30 May 2022.

It is the right time to support our high-impact reporting and authoritative and technical information with some of the best correspondents in the industry. Readers can power Packaging South Asia’s balanced industry journalism and help sustain us by subscribing.

– Naresh Khanna

Subscribe Now


Please enter your comment!
Please enter your name here